The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill
  
The Section 232 investigation gives generic manufacturers an opportunity to highlight supply chain vulnerabilities. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Supply Chain

More from Leadership